Related Experiment Videos
[Clinical experience with ceftizoxime suppositories in bacterial infections in children]
Insights
Ceftizoxime suppositories (CZX-S) offer a safe and effective treatment for bacterial infections in children. This antibiotic preparation showed high success rates and minimal side effects in a clinical trial.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Bacterial infections pose significant health challenges in pediatric populations.
- Conventional antibiotic administration can be difficult in children.
- Ceftizoxime is a third-generation cephalosporin antibiotic with broad-spectrum activity.
Observation:
- A clinical trial evaluated ceftizoxime suppositories (CZX-S) in 10 children with bacterial infections (pneumonia, tonsillitis, pharyngitis, UTI).
- Dosing ranged from 125 mg to 250 mg per suppository, 2-4 times daily, with a daily dose of 17.1-60.0 mg/kg.
- The study monitored therapeutic effectiveness, bacteriological outcomes, and adverse events.
Findings:
- CZX-S demonstrated high therapeutic effectiveness: 'markedly effective' in 3 children and 'effective' in 6.
- Bacteriological eradication of causative organisms was successful in all 4 tested children.
- No significant clinical side effects were observed; eosinophilia in one patient was not definitively linked to CZX-S.
Implications:
- Ceftizoxime suppositories (CZX-S) represent a safe and effective antibiotic option for pediatric bacterial infections.
- This formulation may be particularly beneficial for children experiencing difficulties with conventional antibiotic treatments.
- Further research could explore CZX-S in a wider range of pediatric infectious diseases.
Abstract:
A clinical trial of ceftizoxime suppositories (CZX-S) was performed to evaluate the therapeutic effectiveness in children with bacterial infection. The subjects were 10 children comprising 4 with pneumonia, 3 with lacunar tonsillitis, 2 with pharyngitis, and 1 with UTI. They were given 1 suppository containing either 125 mg or 250 mg of CZX 2 to 4 times a day. The daily per kg body weight dose ranged from 17.1 to 60.0 mg. The result was "markedly effective" in 3, "effective" in 6, and "failure" was recorded in 1. Bacteriologically, successful eradication of causative organisms was confirmed in all the 4 children who underwent the test. No clinical side effects were observed. The only laboratory test abnormality recorded in a single patient was eosinophilia, which was not definitely ascribable to CZX-S. In conclusion, CZX-S have proved to be a clinically safe and effective antibiotic preparation in infantile infection, even in children whose treatment with conventional antibiotics is associated with difficulties.